添加生物素化DYKDDDDK-BAP  10ng至细胞裂解液（相当于1*106细胞数）与原产品Streptavidin磁珠比较添加回收性能。

MagCapture™ Tamavidin®2-REV与原产品比较，低背景，能够回收到目生物素化DYKDDDDK-BAP。

A

用生物素标记HOTAIR RNA的有义链和反义链进行RNAPull-down检测，通过SDS样品缓冲液洗脱，纯化的蛋白质样本通过银染色可检测出来。各RNA探针的反应样本均采用的是K562（5×106细胞数）的总细胞裂解物。

B

利用RNAPull-down实验获得的样本进行免疫印迹实验。一抗是抗Ezh2抗体(D2C9)以及LSD1抗体（C69G12）。

MagCapture™ Tamavidin^®2-REV与原产品相比，可高效率且低背景回收RNA结合蛋白。

产品名称

等电点（pl）※1

耐热性※2

有机溶剂耐性

生物素结合速度系数(ka(M-1S-1))

生物素解离速度系数(kd(S-1))

分子量（四聚物）

Tamavidin^®2

7.4

Tm=85℃

+

(1.0±0.5)×106

检测极限值以下※4

約60kDa

Tamavidin^®2-REV

8

Tm=75℃

–

(1.3±0.5)×106

(1.5±0.4)×10-5

約60kDa

Tamavidin^®2-LPI

6

Tm=65℃

–

(1.2±0.5)×106

检测极限值以下

約60kDa

Tamavidin^®

2-HOT

7.23

高耐熱性

高耐性※3

(3.0±1.7)×105

检测极限值以下

約60kDa

※1

等电点：仅为Tamavidin^®2-LPI的实测值。其他产品是通过氨基酸序列计算出来的数值。

※2

耐热性（TM值）：生物素结合活性加热20分钟可达到加热前的50%。关于Tamavidin®2-HOT，因为在99.9℃加热30分钟结合活性保持在90%以上，所以算不出数值。

※3

高耐性：40-50%DMSO中

※4

检测极限值：5×10-6(kd(S-1))

8W

12W

16w

20w

24w

32w

40w

MRL/lpr,♂

8.9(5.3)

3.7(2.7)

30.1(5.7)

3,504(4,012)

2,100(3,990)

–

–

MRL/lpr,♀

2.5(0.6)

4.5(3.6)

2,055(3,244)

435(481)

436(616)

–

–

NZBWF1,♀

3.2(3.0)

4.6(2.0)

3.3(2.2)

3.1(1.8)

–

476(681)

3,471(4,288)

 1.

The proteasome inhibitor bortezomib attenuates renal fibrosis in mice via the suppression of TGF-β1. Zeniya M, Mori T, Yui N, Nomura N, Mandai S, Isobe K, Chiga M, Sohara E, Rai T, Uchida S. Sci Rep. 2017 Oct 12;7(1):13086.

 2.

A protease-activated receptor-1 antagonist protects against podocyte injury in a mouse model of nephropathy. Yu Guan, Daisuke Nakano, Yifan Zhang, Lei Li, Wenhua Liu, Motohiro Nishida, Takashige Kuwabara, Asahiro Morishita, Hirofumi Hitomi, Kiyoshi Mori, Masashi Mukoyama, Tsutomu Masaki, Katsuya Hirano, Akira Nishiyama. Journal of Pharmacological Sciences, Available online 14, Sep 2017.

 3.

Rosuvastatin pretreatment suppresses distant organ injury following unilateral renal ischemia-reperfusion in hypertensive Dahl salt-sensitive rats. Kanno M, Nakayama M, Zhu WJ, Hayashi Y, Kazama JJ. Nephrology (Carlton). 2017 Sep 22.

 4.

Podocan Is Expressed in Blood and Adipose Tissue and Correlates Negatively With the Induction of Diabetic Nephropathy ? Yasunori Nio, Mitsugi Okawara, Shoki Okuda, Takanori Matsuo, Naoki Furuyama. Journal of the Endocrine Society, Vol.1, Issue 7, Jul 2017, Pages 772-786,

 5.

LXR, PPARγ, and PPARδ Agonists Are Not Sufficient to Demonstrate Therapeutic Potential against Mouse Model of Systemic Lupus Erythematosus. Toyota Tatebe N, Sunahori Watanabe K, Zeggar S, Hiramatsu S, Yan M, Katsuyama T, Katsuyama E, Watanabe H, Sada K, Wada J. Open Journal of Rheumatology and Autoimmune Diseases, 2017, 7, 128-136

 6.

Potent long-acting rhFGF21 analog for treatment of diabetic nephropathy in db/db and DIO mice. Zhao L, Wang H, Xie J, Chen Z, Li X, Niu J. BMC Biotechnol. 2017 Jul 4;17(1):58.

 7.

Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway. Maki T, Maeda Y, Sonoda N, Makimura H, Kimura S, Maeno S, Takayanagi R, Inoguchi T. Metabolism. 2017 Jun;71:33-45.

 8.

Dab1 Contributes to Angiotensin II-Induced Apoptosis via p38 Signaling Pathway in Podocytes. Gao Z, Chen X, Zhu K, Zeng P, Ding G. Biomed Res Int. 2017;2017:2484303.

 9.

Combination of cilostazol and probucol protected podocytes from lipopolysaccharide-induced injury by both anti-inflammatory and anti-oxidative mechanisms. He P, Kawamura H, Takemoto M, Maezawa Y, Ishikawa T, Ishibashi R, Sakamoto K, Shoji M, Hattori A, Yamaga M, Ide S, Ide K, Hayashi A, Tokuyama H, Kobayashi K, Yokote K. J Nephrol. 2016 Dec 22.

10.

Tofogliflozin, a selective inhibitor of sodium-glucose cotransporter 2, suppresses renal damage in KKAy/Ta mice, obese and type 2 diabetic animals. Ishibashi Y, Matsui T, Yamagishi SI. Diab Vasc Dis Res. 2016 Jul 12.

11.

Fermentation of purple Jerusalem artichoke extract to improve the α-glucosidase inhibitory effect in vitro and ameliorate blood glucose in db/db mice. Wang Z, Hwang SH, Lee SY, Lim SS. Nutr Res Pract. 2016 Jun;10(3):282-7.

12.

Nuclear factor erythroid 2-related factor 2 is a critical target for the treatment of glucocorticoid-resistant lupus nephritis. Ebihara S, Tajima H, Ono M. Arthritis Res Ther. 2016 Jun 14;18(1):139.

13.

A novel podocyte gene, semaphorin 3G, protects glomerular podocyte from lipopolysaccharide-induced inflammation. Ishibashi R, Takemoto M, Akimoto Y, Ishikawa T, He P, Maezawa Y, Sakamoto K, Tsurutani Y, Ide S, Ide K, Kawamura H, Kobayashi K, Tokuyama H, Tryggvason K, Betsholtz C, Yokote K. Sci Rep. 2016 May 16;6:25955.

14.

Treatment with anti-IL-6 receptor antibody prevented increase in serum hepcidin levels and improved anemia in mice inoculated with IL-6-producing lung carcinoma cells. Noguchi-Sasaki M, Sasaki Y, Shimonaka Y, Mori K, Fujimoto-Ouchi K. BMC Cancer. 2016 Apr 11;16:270.

15.

Imaging Mass Spectrometry Reveals Acyl-Chain- and Region-Specific Sphingolipid Metabolism in the Kidneys of Sphingomyelin Synthase 2-Deficient Mice. Sugimoto M, Wakabayashi M, Shimizu Y, Yoshioka T, Higashino K, Numata Y, Okuda T, Zhao S, Sakai S, Igarashi Y, Kuge Y. PLoS One. 2016 Mar 24;11(3):e0152191.

16.

Chronic Administration of Visfatin Ameliorated Diabetic Nephropathy in Type 2 Diabetic Mice. Kang YS, Lee MH, Song HK, Kim JE, Ghee JY, Cha JJ, Lee JE, Kim HW, Han JY, Cha DR. Kidney Blood Press Res. 2016;41(3):311-24.

17.

Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney. Morita T, Nakano D, Kitada K, Morimoto S, Ichihara A, Hitomi H, Kobori H, Shiojima I, Nishiyama A. Eur J Pharmacol. Vol.756, p85-91, Jun 2015.

18.

Chelation of dietary iron prevents iron accumulation and macrophage infiltration in the type I diabetic kidney. Morita T, Nakano D, Kitada K, Morimoto S, Ichihara A, Hitomi H, Kobori H, Shiojima I, Nishiyama A. Eur J Pharmacol. Mar 2015.

19.

C-type natriuretic peptide attenuates lipopolysaccharide-induced acute lung injury in mice. Kimura T, Nojiri T, Hosoda H, Ishikane S, Shintani Y, Inoue M, Miyazato M, Okumura M, Kangawa K. J Surg Res. Vol.194(2), p631-7, Apr 2015.

20.

Myocardial infarction accelerates glomerular injury and microalbuminuria in diabetic rats via local hemodynamics and immunity. Dong Z, Gong K, Huang D, Zhu W, Sun W, Zhang Y, Xin P, Shen Y, Wu P, Li J, Lu Z, Zhang X, Wei M. Int J Cardiol.Vol.179, p397-408, Jan 2015.

21.

Effects of Toll-like receptor antagonist 4,5-dihydro-3-phenyl-5-isoxasole acetic acid on the progression of kidney disease in mice on a high-fat diet. Min HS., Kim JE., Lee MH., Song HK., Lee MJ., Lee JE., Kim HW., Cha JJ., Hyun YY., Han JY., Cha DR., Kang YS. Kidney Research and Clinical Practice, 2014.

22.

Ameliorates the Progression of Type 2 Diabetic Nephropathy by Exerting Antioxidative Effects. Ishizawa K., Izawa-Ishizawa Y., Yamano N., Urushihara M., Sakurada T., Imanishi M., Fujii S., Nuno A., Miyamoto L., Kihira Y., Ikeda Y., Kagami S., Kobori H., Tamaki T. PLOS one, 2014

23.

T olvaptan delays the onset of end-stage renal disease in a polycystic kidney disease model by suppressing the increases in kidney volume and renal injury. Aihara M., Fujiki H., Mizuguchi H., Hattori K., Ohmoto K., Ishikawa M., Nagano K. and Yamamura Y. JPET, Feb 2014.

24.

Local Mineralocorticoid Receptor Activation and the Role of Rac1 in Obesity-Related Diabetic Kidney Disease. Yoshida S., Ishizawa K., Ayuzawa N., Ueda K., Takeuchi M., Kawarazaki W., Fujita T., Nagase M.  Nephron Exp Nephrol, Vol.126, p16-24, 2014.

25.

Renin inhibition ameliorates renal damage through prominent suppression of both angiotensin I and II in human renin angiotensinogen transgenic mice with high salt loading. Yoshida S., Ishizawa K., Ayuzawa N., Ueda K., Takeuchi M., Kawarazaki W., Fujita T., Nagase M. Clinical and Experimental Nephrology, Oct 2013.

26.

Fibroblast Growth Factor 21 Improves Insulin Resistance and Ameliorates Renal Injury in db/db Mice. Kim HW., Lee JE., Cha JJ., Hyun YY., Kim JE., Lee MH., Song HK., Nam DH., Han JY., Han SY., Han KH., Kang YS. and Cha DR. Endocrinology, Vol.154(9), Sep 2013.

27.

Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Zheng J., Inoguchi T., Sasaki S., Maeda Y., McCarty MF., Fujii M., Ikeda N., Kobayashi K., Sonoda N., Takayanagi R. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, Vol.304, R110-120, Jun 2013.

28.

Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Zheng J., Inoguchi T., Sasaki S., Maeda Y., McCarty MF., Fujii M., Ikeda N., Kobayashi K., Sonoda N., Takayanagi R. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, Vol.304, R110-120, Jun 2013.

29.

Celastrol, an NF-κB Inhibitor, Improves Insulin Resistance and Attenuates Renal Injury in db/db Mice. J.E.Kim, M.H.Lee, D.H.Nam, H.K.Song, Y.S.Kang, J.E.Lee, H.W.Kim, J.J.Cha, Y.Y.Hyun, S.Y.Han, K.H.Han, J.Y.Han, D.R.Cha. PLOS one 2013.

30.

Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. Zheng J, InoguchiT, SasakiS, MaedaY, McCarty M F, Fujii M, Ikeda N, Kobayashi K, Sonoda N and Takayanagi R. AJP – Regu Physiol,Vo.304(2),p110-120 Jan 2013.

31.

Phycocyanin and phycocyanobilin from Spirulina platensis protect against diabetic nephropathy by inhibiting oxidative stress. J.Zheng, T.Inoguchi, S.Sasaki, Y.Maeda, M.F.McCarty, M.Fujii, N.Ikeda, K.Kobayashi, N.Sonoda, R.Takayanagi. American Journal of Physiology – Regulatory, Integrative and Comparative Physiology, Vol.304, Jan 2013.

32.

Add-On Aliskiren Elicits Stronger Renoprotection Than High-Dose Valsartan in Type 2 Diabetic KKAy Mice That Do Not Respond to Low-Dose Valsartan. Lei B, Nakano D, Fan Y-Y, Kitada K, Hitomi H, Kobori H, Mori H, Masaki T and Nishiyama A. J Pharmacol Sci,Vol.119(2), p131-138,Jun 2012.

33.

Aldosterone Does Not Contribute to Renal p21 Expression During the Development of Angiotensin II-Induced Hypertension in Mice. Nakano D, Lei B, Kitada K, Hitomi H, Kobori H, Mori H, Deguchi K, Masaki T, Minamino T and Nishiyama A. Am J Hypertens, Vol.25(3), p354-358, Mar 2012.

34.

Blockade of Cannabinoid Receptor 1 Improves Insulin Resistance, Lipid Metabolism, and Diabetic Nephropathy in db/db Mice. D. H. Nam., M. H. Lee., J. E. Kim., H. K. Song., Y. S. Kang., J. E. Lee., H. W. Kim., J. J. Cha., Y. Y. Hyun., S. H. Kim., S. Y. Han., K. H. Han, J. Y. Han and Dae Ryong Cha. Endocrinology, Vol.153, No.3, p1387-1396, Mar 2012.

35.

An Angiotensin II Type 1 Receptor Blocker Prevents Renal Injury via Inhibition of the Notch Pathway in Ins2 Akita Diabetic Mice. M. Koshizaka., M. Takemoto., S. Sato., H. Tokuyama., M. Fujimoto., E. Okabe., R. Ishibashi., T. Ishikawa., Y. Tsurutani., S. Onishi., M. Mezawa., P. He., S. Honjo., S. Ueda., Y. Saito and K. Yokote. Experimental Diabetes Research, Vol.2012.

36.

Advanced-glycation-end-product-cholesterol-aggregated-protein accelerates the proliferation of mesangial cells mediated by transforming-growth-factor-beta 1 receptors and the ERK-MAPK pathway. Hirasawa Y, Sakai T, Ito M, Yoshimura H, Feng Y, Nagamatsu T. European Journal of Pharmacology, Vol.672(1-3), p159-168, Dec 2011.

37.

Direct conversion of mouse fibroblasts to hepatocyte-like cells by defined factors. S. Sekiya., A. Suzuki. Nature 475,390-393(2011)

38.

Aliskiren improves insulin resistance and ameliorates diabetic vascular complications in db/db mice. Y. S. Kang., M. H. Lee., H. K. Song., Y. Y. Hyun., J. J. Cha., G. J. Ko., S. H. Kim., J. E. Lee., J. Y. Han. and D. R. Cha. Nephrol. Dial. Transplant. (2011) 26 (4): 1194-1204.

39.

Intramuscular transplantation of engineered hepatic tissue constructs corrects acute and chronic liver failure in mice. N. N.-Alvarez., A. S.-Gutierrez., Y. Chen., J. C.-Corbalan., W. Hassan., S. Kobayashi., Y. Kondo., M. Iwamuro., K. Yamamoto., E. Kondo., N. Tanaka., I. J. Fox., N. Kobayashi. Journal of Hepatology Vol. 52(2), p211-219, 2010.

40.

CCR2 antagonism improves insulin resistance, lipid metabolism, and diabetic nephropathy in type 2 diabetic mice. Kang,Y.S.,Lee,M.H.,Song,H.K.,Ko,G.J.,Kwon,O.S.,Lim,T.K.,Kim,S.H.,Han,S.Y.,Hyun,K. Kidney International, Vol.78, p883-894, November(1), 2010

41.

Effect of interleukin-6 receptor blockage on renal injury in apolipoprotein E-deficient mice. Tomiyama-Hanayama M, Rakugi H, Kohara M, Mima T, Adachi Y, Ohishi M, Katsuya T, Hoshida Y, Aozasa K, Ogihara T and Nishimoto N. AJP – Renal Physiol, Vol.297(3), p679-684, Sep 2009.

42.

Elevated Urinary Cr Loss Induces a Reduction in Renal Cr Concentration and the Negative Cr Balance in Streptozotocin-Induced Diabetic Mice. MITA Y, ISHIHARA K, ISHIGURO M, TAKEDA M, HATTORI R, MURAKAMI K, YAMADA A, YASUMOTO K. Journal of Nutritional Science and Vitaminology,Vol. 54(4), p303-308, 2008.

43.

Modification of mineralocorticoid receptor function by Rac1 GTPase: implication in proteinuric kidney disease. Shibata S, Nagase M, Yoshida S, Kawarazaki W, Kurihara H, Tanaka H, Miyoshi J, Takai Y and Fujita T. NTURE MEDFICINE, Vol.14(12), p1370-1376, Dec 2008.

44.

Rubratoxin B induces interleukin-6 secretion in mouse white Adipose tissues and 3T3-L1 adipocytes. Keiko Iwashita,Hitoshi Nagashima. Toxicology Letters, Vol.182, p79-83, 2008.

45.

Deterioration of atherosclerosis in mice lacking angiotensin II type 1A receptor in bone marrow-derived cells. Kato,H., Ishida,J., Nagano,K., Honjo,K., Sugaya,T., Takeda,N., Sugiyama,F., Yagami,K., Fujita,T., Nangaku,M., and Fukamizu, A. Lab Invest., Vol.88(7), p731-9, 2008.

46.

Differentiation of mouse and human embryonic stem cells into hepatic lineages. Shiraki,N., Umeda,K., Sakashita,N., Takeya,M., Kume,K., and Kume, S. Genes to Cells, Vol.13, p731-746, 2008.

47.

Effect of Lactobacillus jonsonii La1 on immune function and serum albumin in aged and malnourished aged mice. Kaburagi, T., Yamano, T., Fukushima, Y, Yoshino, H., Mito, N., and Sato, K. Nutrition Vol.24, p342-350, 2007.

48.

Differentiation of mouse embryonic stem cells to hepatocyto-like cells by co-culture with human liver nonparenchymal cell lines. Soto-Gutierrez, A., Navarro-Alvarez, N., Zhao, D., Rivas, J.D., Rivas-Carillo, J.D., Lebkowski, J., Tanaka, N., Fox, I.J., and Kobayashi, N. Nature Protocols. Electronic Edition Vol.2, p347-356, 2007.

49.

Construction and transplantation of an engineered hepatic tissue using a polyaminourethane-coated nonwoven polytetrafluoroethylene fabric. Soto-Gutierrez, A., Navarro-Alvarez, N., Rivas, J.D., Tanaka, K., Chen, Y., Misawa, H., Okitsu, T., Noguchi, H., Tanaka, N., and Kobayashi, N. Transplantation, Vol.83, p129-137, 2007.

50.

Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Fujii, M., Inoguchi, T., Maeda, Y., Sasaki, S., Sawada, F., saito, R., Kobayashi, K., Sumitomo, H., and Takayanagi, R. Kidney International, Vol.72, p473-480, 2007.

51.

Characterization of cytochrome P450 expression in murine embryonic stem cell-derived hepatic tissue system. Tsutsui, M., Ogawa, S., Inada, Y., Tomioka, E., Kamiyoshi, A., Tanaka, S., Kishida, S., Nishiyama, M., Murakami, M., Kuroda, J., Hashikura, Y., Miyagawa, S., satoh, F., shibata, N., and Tagawa, Y. Drug Metabolism and Disposition, Vol.34, p696-701, 2006.

52.

Growth factor midkine is involved in the pathogenesis of diabetic nephropathy. Kosugi, T., Yuzawa, Y., sato, W., Kawai, H., Matsuo, S.,Takei,Y.,Muramatsu,T., and Kadomatsu,K. Am J Pathology Vol.168, p9-19, 2006.

53.

Characterization of cytochrome P450 expression in murine embryonic stem cell-derived hepatic tissue system. Tsutsui,M., Ogawa,S., Inada,Y., Tomioka,E., Kammiyoshi,A., Tanaka,S., Kishida,T., Nishiyama,M., Murakami,M., Kuroda,J., Hashikura,Y., Miyagawa,S., Satoh,F., Shibata,N., and Tagawa,Y. The American Society for Pharmacology and Experimental Thera- peutics, Vol.34, p696-701,2006.

54.

Supplementation with chromium picolinate recovers renal Cr concentration and improves carbohydrate metabolism and renal function in type 2 diabetic mice. Mita, Y., Ishihara, K., Fukuchi, Y., Fukuya, Y., and Yasumoto, K. Biological Trace Element Research, Vol.105, p229-248, 2005.

55.

6-Methylsulfinylhexyl Isothiocyanate, an Antioxidant Derived from Wasabia japonica MATUM, Ameliorates Diabetic Nephropathy in Type 2 Diabetic Mice. FUKUCHI Y, KATO Y, OKUNISHI I, MATSUTANI Y, OSAWA T, NAITO M. Food Science and Technology Research, Vol.10(3), p290-295, 2004.

56.

Tissue array substratum composed of histological sections: A new platform for orienting differentiation of embryonic stem cells towards hepatic lineage. Takeuchi, T., Ochiya, T., and Takezawa, T. Tissue Eng Part A. 2008 Feb;14(2):267-74

 1.

Protective Role of PEDF-Derived Synthetic Peptide Against Experimental Diabetic Nephropathy. Ishibashi Y, Matsui T, Taira J, Higashimoto Y, Yamagishi S. Horm Metab Res. 2016 Sep;48(9):613-9.

 2.

A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats. Takeshige Y, Fujisawa Y, Rahman A, Kittikulsuth W, Nakano D, Mori H, Masaki T, Ohmori K, Kohno M, Ogata H, Nishiyama A. Hypertens Res. 2016 Jun;39(6):415-22.

 3.

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Takakura S, Toyoshi T, Hayashizaki Y, Takasu T. Life Sci. 2016 Feb 15;147:125-31.

 4.

An Atherogenic Paigen-Diet Aggravates Nephropathy in Type 2 Diabetic OLETF Rats. Masanori Nozako, Takashi Koyama, Chifumi Nagano, Makoto Sato, Satoshi Matsumoto, Kiminobu Mitani, Reiko Yasufuku, Masayuki Kohashi, and Tomohiro Yoshikawa. PLoS One. 2015; 10(11): e0143979.

 5.

Oxygenated Static Preservation of Donation after Cardiac Death Liver Grafts Improves Hepatocyte Viability and Function.. Yu J, Murakami M, Aoki T, Jiang B, Jin Z, Koizumi T, Kusano M, Kamijo R, Miyamoto Y, Enami Y, Watanabe M, Otsuka K. Eur Surg Res. 2016;56(1-2):1-18.

 6.

Chronic Running Exercise Alleviates Early Progression of Nephropathy with Upregulation of Nitric Oxide Synthases and Suppression of Glycation in Zucker Diabetic Rats. Daisuke Ito, Pengyu Cao, Takaaki Kakihana, Emiko Sato, Chihiro Suda, Yoshikazu Muroya, Yoshiko Ogawa, Gaizun Hu, Tadashi Ishii, Osamu Ito, Masahiro Kohzuki, and Hideyasu Kiyomoto. PLoS One. 2015; 10(9): e0138037.

 7.

Effect of ipragliflozin, an SGLT2 inhibitor, on progression of diabetic microvascular complications in spontaneously diabetic Torii fatty rats. Takakura S, Toyoshi T, Hayashizaki Y, Takasu T. Life Sci. Volume 147, 15 February 2016, Pages 125–131

 8.

Automated image analysis of a glomerular injury marker desmin in SDT rats treated with losartan. Kakimoto T, Okada K, Hirohashi Y, Relator R, Kawai M, Iguchi T, Fujitaka K, Nishio M, Kato T, Fukunari A, Utsumi H. J Endocrinol, Vol.222(1), p43-51, Jul 2014.

 9.

Exercise training upregulates nitric oxide synthases in the kidney of rats with chronic heart failure. Ito D., Ito O., Mori N., Cao P., Suda C., Muroya Y., Hao K., Shimokawa H., Kohzuki M. Clinical and Experimental Pharmacology and Physiology, Vol.40(9), p617-625, Sep 2013.

10.

Sulodexide improves renal function through reduction of vascular endothelial growth factor in type 2 diabetic rats. Cha JJ., Kang YS., Hyun YY., Han SY., Jee YH., Han KH., Han JY., Cha DR. Life Sciences, Vol.92(23), p1118-1124, Jun 2013.

11.

Aberrant Activation of the Intrarenal Renin-Angiotensin System in the Developing Kidneys of Type 2 Diabetic Rats. Fan YY., Kobori H., Nakano D., Hitomi H., Mori H., Masaki T., Sun YX., Zhi N., Zhang L., Huang W., Zhu B., Li P. and Nishiyama A. Horm Metab Res, Vol.45(5), p338-343, May 2013.

12.

Effects of exercise training on nitric oxide synthase in the kidney of spontaneously hypertensive rats. Ito D, Ito O, Cao P, Mori N, Suda C, Muroya Y, Takashima K, Ito S, Kohzuki M. Clinical and Experimental Pharmacology and Physiology, Vol.40(2), p74-82, Feb 2013.

13.

Renal Sympathetic Denervation Suppresses De Novo Podocyte Injury and Albuminuria in Rats With Aortic Regurgitation. Rafiq K, Noma T, Fujisawa Y, Ishihara Y, Arai Y, Nurun Nabi A H M, Suzuki F, Nagai Y, Nakano D, Hitomi H, Kitada K, Urushihara M, Kobori H, Kohno M, Nishiyama A. Circulation,Vol.125, p1402-1413,2012.

14.

GLP-1 analog liraglutide protects against oxidative stress and albuminuria in streptozotocin-induced diabetic rats via protein kinase A-mediated inhibition of renal NAD(P)H oxidases. Hendarto H, Inoguchi T, Maeda Y, Ikeda N, Zheng J, Takei R, Yokomizo H, Hirata E, Sonoda N, Takayanagi R. Metabolism – Clinical and Experimental,Vol.61(10), p1422-1434, Oct 2012.

15.

N-type Calcium Channel Inhibition With Cilnidipine Elicits Glomerular Podocyte Protection Independent of Sympathetic Nerve Inhibition. Lei　B,Nakano D, Fujisawa Y, Liu Y, Hitomi H, Kobori H, Mori H, Masaki T, Asanuma K, Tomino Y and Nishiyama A. J Pharmacol Sci, Vol.119(4), p359-367, Aug 2012.

16.

Beneficial effect of ubiquinol, the reduced form of coenzyme Q10, on cyclosporine nephrotoxicity. Ishikawa A, Homma Y. Int. braz j urol, Vol.38(2) 2012.

17.

Effect of Eplerenone, a Selective Aldosterone Blocker, on the Development of Diabetic Nephropathy in Type 2 Diabetic Rats . Ahn J H, Hong H C, Cho M J, Kim Y J, Choi H Y, Eun C R, Yang S J, Yoo H J, Kim H Y, Seo J A, Kim S G, Choi K M, Baik S H, Choi D S and Kim N H.  Diabetes Metab J, Vol36(2), p128-135, Apr 2012.

18.

P2X7 receptor antagonism attenuates the hypertension and renal injury in Dahl salt-sensitive rats. X. Ji., Y. Naito., G. Hirokawa., H. Weng., Y. Hiura., R. Takahashi and N. Iwai. Hypertension Research, 35, p173-179 (February 2012)

19.

The effects of iridium on the renal function of female Wistar rats. Iavicoli I, Fontana L, Marinaccio A, Alimonti A, Pino A, Bergamaschi A, Calabrese E J. Ecotoxicology and Environmental Safety, Vol.74(7), p1795-1799, Oct 2011.

20.

Effect of methylmercury administration on choroid plexus function in rats. M. Nakamura., A. Yasutake., M. Fujimura., N. Hachiya and M. Marumoto. Archives of Toxicology Vol. 85, (2011), p911-918,

21.

Renal preservation effect of ubiquinol, the reduced form of coenzyme Q10. A. Ishikawa., H. Kawarazaki., K. Ando., M. Fujita., T. Fujita and Y. Homma. Clinical and Experimental Nephrology Vol.15, Number 1 (2011), p30-33,

22.

Effects of mineralocorticoid receptor blockade on glucocorticoid-induced renal injury in adrenalectomized rats. K. Rafiq., D. Nakano., G. Ihara., H. Hitomi., Y. Fujisawa., N. Ohashi., H. Kobori., Y. Nagai., H. Kiyomoto., M. Kohno and A. Nishiyama. J Hypertens. 2011 February; 29(2): p290-298.

23.

Regression of superficial glomerular podocyte injury in type 2 diabetic rats with overt albuminuria: effect of angiotensin II blockade. Ihara G, Kiyomoto H, Kobori H, Nagai Y, Ohashi N, Hitomi H, Nakano D, Pelisch N, Hara T, Mori T, Ito S, Kohno M and Nishiyamad A. J Hypertens, Vol.28(11), p2289-2298, Nov 2010 .

24.

Visfatin is upregulated in type-2 diabetic rats and targets renal cells. Kang Y S, Song H K, Lee M H, Ko G J, Han J Y, Han S Y, Han K H, Kim H K and Cha D R. Kidney International, Vol.78, p170-181, 2010.

25.

High Salt Intake Elevated Blood Pressure but not Changed Circadian Blood Pressure Rhythm in Otsuka Long-Evans Tokushima Fatty (OLETF) Rat. Matsumoto M, Tsujino T, Naito Y, Sakoda T, Ohyanagi M, Nonaka H and Masuyama T. Clinical and Experimental Hypertension, Vol.31(3) , p271-280, 2009

26.

Cold Preservation of the Liver With Oxygenation by a Two-Layer Method. Odaira,M., Aoki,T., Miyamoto,Y., Yasuhara,R., Jin,Z., Yu,J., Nishino,N., Yamada,K., Kusano,T., Hayashi,K., Yasuda,D., Koizumi,T., Mitamura,K., Enami,Y., Niiya,T., Murai,N., Kato,H., Shimizu,Y., Kamijyo,R., and Kusano, M. Journal of Surgical Research, Volume 152(2), p209-217, 2009.

27.

Effect of Astaxanthin in Combination with α-Tocopherol or Ascorbic Acid against Oxidative Damage in Diabetic ODS Rats. NAKANO M, ONODERA A, SAITO E, TANABE M, YAJIMA K, TAKAHASHI J, CHUYEN N V. Journal of Nutritional Science and Vitaminology, Vol.54(4), p329-334, 2008.

28.

Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Ko G J, Kang Y S, Han S Y, Lee M H, Song H K, Han K H, Kim H K, Han J Y and Cha D R. Nephrol. Dial. Transplant, Vol23(9), p2750-2760, 2008.

29.

Strict angiotensin blockade prevents the augmentation of intrarenal angiotensin II and podocyte abnormalities in type 2 diabetic rats with microalbuminuria. Nishiyama A, Nakagawa T, Kobori H, Nagai Y, Okada N, Konishi Y, Morikawa T, Okumura M, Meda I, Kiyomoto H, Hosomi N, Mori T, Ito S and Imanishie M. J Hypertens, Vol.26(9), p1849-1859, Sep 2008.

30.

Angiotensin receptor blockers improve insulin resistance in type 2 diabetic rats by modulating adipose tissue. Lee M H, Song H K, Ko G J, Kang Y S, Han S Y, Han K H, Kim H K, Han J Y and Cha D R. Kidney International, Vo.l74, p890-900, 2008.

31.

Cell processing on polyimide surface patterned by rubbing. Matsumoto,N.,Hiruma,H.,Nagaoka,S.,Fujiyama,K.,Kaneko,A., and Kawakami, H.. Polymers for Advanced Technologies, Vol.19(8), p1002-1008, 2008.

32.

Pitavastatin ameliorates albuminuria and renal mesangial expansion by downregulating NOX4 in db/db mice. Fujii M, Inoguchi T, Maeda Y, Sasaki S, Sawada F, Saito R, Kobayashi K, Sumimoto H and Takayanagi R. Kidney International, Vol.72, p473-480, 2007.

33.

Antidiabetic effect of long-term supplementation with Siraitia grosvenori on the spontaneously diabetic Goto-Kakizaki rat. Suzuki, Y.A., Tomoda, M., Murata Y., Inui, H., Sugiura, M., and Nakano, Y. British J Nutrition, Vol.97, p770-775, 2007.

34.

Hepatocyte transplantation from steatotic liver in a rat model. Hayashi, K., Aoki, T., Jin, Z., Wang, H., Nishino, N., Kusano, T., Yasuda, D., Koizumi, T., Enami, Y., and Odaira, M. J Surgical Research, Vol.142, p104-112, 2007

35.

Dietary nitrite inhibits early glomerular injury in streptozotocin-induced diabetic nephropathy in rats. Ohtake, K., Ishiyama, Y., Uchida, H., Muraki, E., and Kobayashi, J. Nitric Oxide, Vol.17, p75-81, 2007.

36.

High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: A new rat model of diabetic nephropathy. Sugano M, Yamato H, Hayashi T, Ochiai H, Kakuchi J, Goto S, Nishijima F, Iino N, Kazama J J, Takeuchi T, Mokuda O, Ishikawa T, Okazaki R. Nutrition, Metabolism and Cardiovascular Diseases, Vol.16(7), p477-484, Oct 2006.

37.

Spironolactone ameriolates renal injuary and connective tissue growth factor expression in type II diabetic rats. Han, K.H., Kang, Y.S., Han, S.Y., Jee, Y.H., Lee, M.H., Han, J.Y., Kim, H.K., Kim, Y.S., and Cha, D.R. Kidney International, Vol.70, p111-120, 2006.

38.

High functional hollow fiber membrane modified with phospholipid polymers for a liver assist bioreactor. Ye, S.H., Watanabe, J., Takai, M., Iwasaki, Y., and Ishihara, K. Biomaterials, Vol.27, p1955-1962, 2006.

39.

Spironolactone prevents diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats. Han,S.Y., Kim, C.H., Kim, H.S., Jee, Y.H., Song, H.K., Lee, M.H., Han, K.H., Kim, H.K., Kang, Y.S., Han, J.Y., Kim, Y.S. and Cha, D.R. J Am Soc Nephrology, Vol.17, p1362-1372, 2006.

40.

Efficient in vivo xenogeneic retroviral vector-mediated gene transduction into human Hepatocytes. Kentaro Emoto, Chise Tateno, Hiroshi Hino, Hironobu Amano, Yasuhiro Imaoka, Kinji Asahina, Toshimasa, Asahara, and Katsutoshi Yoshizato. Human Gene Therapy, Vol.16, p1168-1174, 2005.

41.

In vivo engineering of metabolically active hepatic tissue in a neovascularized subcutaneous cavity. Yokoyama, T., Ohashi, K., Kuge, H., Kanehiro, H., Iwata, H., Yamato, M., and Nakajima, Y. Am J Transplantation, Vol.6, p50-59, 2005.

42.

Effect of retinoic acid in experimental diabetic nephropathy. Han, S.Y., so, G.A., Jee, Y.H., Han, K.H., Kang, Y.S., Kim, H.K., Kang, S.W., Han, D.S., Han, J.Y., and Cha, D.R. Immunol Cell Biol, Vol.82, p568-576, 2004.

43.

Enhanced activity of serum and urinary hyaluronidases in streptozotocin-induced diabetic Wister and GK rats. Ikegami-Kawai, M., Okuda, R., Nemoto, T., Inada, N., and Takahashi, T. Glycobiology, Vol.14, p65-72, 2004.